Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Takuji IwaseShigehira SajiKotaro IijimaKenji HigakiShoichiro OhtaniYasuyuki SatoYasuo HozumiYoshie HasegawaYasuhiro YanagitaHiroyuki TakeiMaki TanakaHideji MasuokaMasahiko TanabeChiyomi EgawaYoshifumi KomoikeToshitaka NakamuraHiroshi OhtsuHirofumi MukaiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.